scispace - formally typeset
Search or ask a question
Institution

Foundation Medicine

About: Foundation Medicine is a based out in . It is known for research contribution in the topics: Cancer & Targeted therapy. The organization has 430 authors who have published 1085 publications receiving 41789 citations.
Topics: Cancer, Targeted therapy, Lung cancer, Breast cancer, KRAS
Papers published on a yearly basis
Papers
More filters
Journal Article•DOI•
Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

[...]

Eytan M. Stein1, Ying Huang2, Uma Borate3, Maria R. Baer4, Wendy Stock5, Tibor Kovacsovics6, William Blum7, Gary J. Schiller8, Rebecca L. Olin9, James M. Foran10, Mark R. Litzow10, Tara L. Lin11, Prapti A. Patel12, Matthew C. Foster13, Michael Boyiadzis14, Robert H. Collins12, Jo-Anne Vergilio15, Nyla A. Heerema2, Leonard Rosenberg, Ashley O. Yocum, Timothy L. Chen2, Franchesca Druggan2, Sonja Marcus, Mona Stefanos, Jordan Chervin1, Abigail B. Shoben2, Brian J. Druker3, Amy Burd, John C. Byrd2, Ross L. Levine1, Alice S. Mims2 •
Memorial Sloan Kettering Cancer Center1, Ohio State University2, Oregon Health & Science University3, University of Maryland, Baltimore4, University of Chicago5, Huntsman Cancer Institute6, Emory University7, University of California, Los Angeles8, University of California, San Francisco9, Mayo Clinic10, University of Kansas11, University of Texas Southwestern Medical Center12, University of North Carolina at Chapel Hill13, University of Pittsburgh14, Foundation Medicine15
05 Nov 2020-Blood
TL;DR: The results of a Phase 2 expansion and Phase 1b of the Beat AML Master Trial Phase 2/1b sub-study to assess the efficacy of Tx of newly diagnosed ND IDH2m AML pts ≥ 60 years of age with ENA monotherapy (ENAm) and subsequent response-driven addition of AZA Tx supported distinct biology between these subsets.

3 citations

Journal Article•DOI•
PD-L1 Status and Survival in Patients With Lung Cancer-Reply.

[...]

Peter Grant Miller1, Gerald Li2, Gaurav Singal2•
Harvard University1, Foundation Medicine2
27 Aug 2019-JAMA

3 citations

Journal Article•DOI•
1193P Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib

[...]

Rafal Dziadziuszko1, Fabrice Andre2, Wai-Ki Yip3, X. Wu4, Joel Skoletsky3, Ryan Woodhouse3, T. Hung4, Timothy R. Wilson4, Todd Riehl4, Lucas Dennis3, Meijuan Li3 •
Gdańsk Medical University1, Institut Gustave Roussy2, Foundation Medicine3, Genentech4
01 Sep 2020-Annals of Oncology

3 citations

Journal Article•DOI•
Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation

[...]

Siraj M. Ali1, Philip J. Stephens1, Vincent A. Miller1, Jeffrey S. Ross2, Sumanta K. Pal3 •
Foundation Medicine1, Albany Medical College2, City of Hope National Medical Center3
01 Aug 2015-European Urology
TL;DR: A 74-yr-old woman with fatigue, liver function test abnormalities, and abdominal pain, who underwent cytoreductive nephrectomy with findings of a pT1bN0 clear cell renal cell carcinoma, has genomic profiling to ascertain whether other targeted strategies might be relevant.

3 citations

Journal Article•DOI•
Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma.

[...]

Bethany Bustamante1, Risha Sinha1, Briana Rice1, Aaron Nizam1, Weiwei Shan1, Gary L. Goldberg1, Veena S. John1, Doug I Lin2, Natalie Danziger2, Dean Pavlick2, Julia A. Elvin2, Marina Frimer1, Marina Frimer3 •
Hofstra University1, Foundation Medicine2, The Feinstein Institute for Medical Research3
15 Jun 2021
TL;DR: GLOH status may be a meaningful prognostic biomarker within the CN-H tumors and possibly across EC-MS, and CGP can also assess gLoh status with gLOH-H most commonly seen in CN- H tumors.
Abstract: PURPOSEHomologous recombination deficiency, identified by homologous recombination deficiency gene alterations or high percentage of genome-wide loss of heterozygosity (gLOH), is associated with im...

3 citations

Authors

Showing all 430 results

NameH-indexPapersCitations
Bartolome R. Celli11865063423
Vincent A. Miller10564765822
Vera J. Suman7629435533
Adam Brufsky7446027570
Jeffrey S. Ross7034721334
Philip J. Stephens6923629559
Kai Wang69109521841
Siraj M. Ali6546325639
Jeffrey S. Ross5934320600
Roman Yelensky5716415073
Doron Lipson5718017014
Garrett M. Frampton5521522373
Geoffrey R. Oxnard5424514325
Brian M. Alexander502649200
Jeffrey P. Gregg461074882
Network Information
Related Institutions (5)
University of Texas MD Anderson Cancer Center
92.5K papers, 4.7M citations

94% related

Memorial Sloan Kettering Cancer Center
65.3K papers, 4.4M citations

92% related

Roswell Park Cancer Institute
19.5K papers, 944.8K citations

91% related

City of Hope National Medical Center
16.4K papers, 755.4K citations

91% related

The Royal Marsden NHS Foundation Trust
13.4K papers, 668.8K citations

90% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2021137
2020144
2019138
2018142
2017193
2016112